鞘内尼卡地平治疗蛛网膜下腔出血后脑血管痉挛与迟发性脑缺血减少相关:基于倾向评分的回顾性分析
该回顾性研究纳入2012—2017年埃默里大学医院神经科学ICU收治的1351例非创伤性蛛网膜下腔出血患者,其中422例因脑血管痉挛接受鞘内尼卡地平治疗,并与SAHIT数据库中未接受该治疗者进行倾向评分比较。结果显示鞘内尼卡地平与迟发性脑缺血风险降低(OR 0.61,95%CI 0.44-0.84)及良好功能预后相关(OR 2.17,95%CI 1.61-2.91),但脑室腹腔分流率升高。
要点
- 鞘内尼卡地平与迟发性脑缺血风险降低相关(OR 0.61)。
- 治疗组良好功能预后(mRS≤2)的OR为2.17。
- 治疗组脑室腹腔分流率更高(19.9% vs 8.8%),细菌性脑室炎未见增加。
核心结论
- 鞘内尼卡地平与倾向评分匹配对照相比,与改善预后及减少迟发性脑缺血相关。
- 治疗组永久性脑脊液分流需求增加,但无其他安全性问题。
- 这些数据可供未来蛛网膜下腔出血随机对照试验选择干预措施时参考。
研究设计与样本
- 回顾性队列研究,纳入2012—2017年埃默里大学医院神经科学ICU收治的非创伤性蛛网膜下腔出血(动脉瘤性或特发性)患者。
- 共分析1351例患者,其中422例诊断为脑血管痉挛并接受鞘内尼卡地平治疗,859例无血管痉挛。
- 采用倾向评分模型与未接受鞘内尼卡地平的SAHIT数据库患者进行比较。
- 主要结局为迟发性脑缺血,次要结局为长期功能结局与不良事件。
主要发现
- 与无血管痉挛患者相比,治疗组更年轻(平均年龄51.1±12.4岁 vs 56.7±14.1岁,p<0.001),WFNS评分和改良Fisher分级更高。
- 治疗组行动脉瘤夹闭的比例高于血管内治疗(30.3% vs 11.3%,p<0.001)。
- 鞘内尼卡地平使77.3%的治疗患者每日平均经颅多普勒流速下降。
- 与未接受鞘内尼卡地平者相比,细菌性脑室炎发生率无增加(3.1% vs 2.7%,p>0.1),但脑室腹腔分流率更高(19.9% vs 8.8%,p<0.01)。
- 与SAHIT数据库倾向评分比较,鞘内尼卡地平治疗发生迟发性脑缺血的OR为0.61(95%CI 0.44-0.84),良好功能结局(mRS≤2)的OR为2.17(95%CI 1.61-2.91)。
关键数值与推荐
- 迟发性脑缺血:鞘内尼卡地平治疗OR 0.61(95%CI 0.44-0.84)。
- 良好功能结局(mRS≤2):OR 2.17(95%CI 1.61-2.91)。
- 细菌性脑室炎:3.1% vs 2.7%(p>0.1)。
- 脑室腹腔分流:19.9% vs 8.8%(p<0.01)。
- 经颅多普勒流速下降:见于77.3%的治疗患者。
临床怎么用
- 对蛛网膜下腔出血后脑血管痉挛患者,鞘内尼卡地平可作为候选治疗选择,但需权衡永久分流风险。
- 治疗期间应监测脑室腹腔分流需求及脑室炎等不良事件。
- 该回顾性证据可为未来随机对照试验的设计提供参考。
局限性
- 为单中心回顾性研究,与SAHIT数据库的比较依赖倾向评分模型,可能存在残余混杂。
- 治疗组与对照组的基线特征存在差异,如年龄、WFNS评分、改良Fisher分级及动脉瘤处理方式。
- 原文未报告随机化、盲法及具体混杂因素调整细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cerebral vasospasm and delayed cerebral ischemia (DCI) contribute to poor outcome following subarachnoid hemorrhage (SAH). With the paucity of effective treatments, the authors describe their experience with intrathecal (IT) nicardipine for this indication. METHODS: Patients admitted to the Emory University Hospital neuroscience ICU between 2012 and 2017 with nontraumatic SAH, either aneurysmal or idiopathic, were included in the analysis. Using a propensity-score model, this patient cohort was compared to patients in the Subarachnoid Hemorrhage International Trialists (SAHIT) repository who did not receive IT nicardipine. The primary outcome was DCI. Secondary outcomes were long-term functional outcome and adverse events. RESULTS: The analysis included 1351 patients, 422 of whom were diagnosed with cerebral vasospasm and treated with IT nicardipine. When compared with patients with no vasospasm (n = 859), the treated group was significantly younger (mean age 51.1 ± 12.4 years vs 56.7 ± 14.1 years, p < 0.001), had a higher World Federation of Neurosurgical Societies score and modified Fisher grade, and were more likely to undergo clipping of the ruptured aneurysm as compared to endovascular treatment (30.3% vs 11.3%, p < 0.001). Treatment with IT nicardipine decreased the daily mean transcranial Doppler velocities in 77.3% of the treated patients. When compared to patients not receiving IT nicardipine, treatment was not associated with an increased rate of bacterial ventriculitis (3.1% vs 2.7%, p > 0.1), yet higher rates of ventriculoperitoneal shunting were noted (19.9% vs 8.8%, p < 0.01). In a propensity score comparison to the SAHIT database, the odds ratio (OR) to develop DCI with IT nicardipine treatment was 0.61 (95% confidence interval [CI] 0.44-0.84), and the OR to have a favorable functional outcome (modified Rankin Scale score ≤ 2) was 2.17 (95% CI 1.61-2.91). CONCLUSIONS: IT nicardipine was associated with improved outcome and reduced DCI compared with propensity-matched controls. There was an increased need for permanent CSF diversion but no other safety issues. These data should be considered when selecting medications and treatments to study in future randomized controlled clinical trials for SAH.
引用
- Sadan O, Waddel H, Moore R, et al. Does intrathecal nicardipine for cerebral vasospasm following subarachnoid hemorrhage correlate with reduced delayed cerebral ischemia? A retrospective propensity score-based analysis. J Neurosurg. 2021. PMID: 34087804. doi:10.3171/2020.12.JNS203673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。